Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Innocenti

Showing results (1-10 of 186) with videos related to

Pageof 19
Sort By:
JCO Oncology Practice|April 1, 2021
Reply to A. D. King et alFederico Innocenti
Pharmacogenomics|October 19, 2012
One SNP for both cancer risk and survival in colorectal cancer: two for the price of one?Federico Innocenti
Clinical Advances in Hematology & Oncology : H&O|February 24, 2006
UGT1A1 genotyping in patients undergoing treatment with irinotecanFederico Innocenti
F1000Research|April 15, 2017
Bringing a genomic perspective to the safety of drug treatment in oncologyFederico Innocenti
The Journal of Supportive Oncology|February 3, 2007
Challenges in the development and use of pharmacogenomic markers in oncologyFederico Innocenti
Journal of the National Cancer Institute|November 9, 2014
DPYD variants to predict 5-FU toxicity: the ultimate proofFederico Innocenti
Pharmacogenomics|August 23, 2012
Moving away from candidate genes: a 'genome-wise' discovery of gemcitabine myelotoxicityFederico Innocenti
JCO Oncology Practice|December 3, 2021
All You Need to Know About <i>UGT1A1</i> Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly GuideSpinel Karas, Federico Innocenti
Leukemia & Lymphoma|August 23, 2006
MTHFR and ALL risk: a challengeGiuseppe Toffoli, Federico Innocenti
Biomarkers in Medicine|June 27, 2012
Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Daniel Crona, Federico Innocenti
Pageof 19

Showing results (1-10 of 186) with videos related to

Sort By:
Pageof 19
JCO Oncology Practice|April 1, 2021
Reply to A. D. King et alFederico Innocenti
Pharmacogenomics|October 19, 2012
One SNP for both cancer risk and survival in colorectal cancer: two for the price of one?Federico Innocenti
Clinical Advances in Hematology & Oncology : H&O|February 24, 2006
UGT1A1 genotyping in patients undergoing treatment with irinotecanFederico Innocenti
F1000Research|April 15, 2017
Bringing a genomic perspective to the safety of drug treatment in oncologyFederico Innocenti
The Journal of Supportive Oncology|February 3, 2007
Challenges in the development and use of pharmacogenomic markers in oncologyFederico Innocenti
Journal of the National Cancer Institute|November 9, 2014
DPYD variants to predict 5-FU toxicity: the ultimate proofFederico Innocenti
Pharmacogenomics|August 23, 2012
Moving away from candidate genes: a 'genome-wise' discovery of gemcitabine myelotoxicityFederico Innocenti
JCO Oncology Practice|December 3, 2021
All You Need to Know About <i>UGT1A1</i> Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly GuideSpinel Karas, Federico Innocenti
Leukemia & Lymphoma|August 23, 2006
MTHFR and ALL risk: a challengeGiuseppe Toffoli, Federico Innocenti
Biomarkers in Medicine|June 27, 2012
Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Daniel Crona, Federico Innocenti
Pageof 19